Thymogen – (38101-59-6)

Oglufanide is a synthetic dipeptide immunomodulator initially developed to treat severe infectious diseases. It is composed of L-glutamic acid and L-tryptophan linked by a peptide bond. Oglufanide is primarily recognized for its role in regulating the body’s immune response, making it a potential treatment for chronic hepatitis C viral infection. It is administered intranasally and has demonstrated properties as an immunomodulator, angiogenesis modulator, and antineoplastic agent.

In the context of cancer research, Oglufanide has shown antitumor and anti-angiogenic activities. It inhibits vascular endothelial growth factor (VEGF) and has been studied for its ability to stimulate the immune response against HCV and intracellular bacterial infections. Clinical trials have explored its efficacy in treating ovarian and colorectal cancers, among other conditions.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://pubchem.ncbi.nlm.nih.gov/compound/100094
https://www.medchemexpress.com/Oglufanide.html
https://www.medkoo.com/products/21349
https://pubmed.ncbi.nlm.nih.gov/38732260/
https://www.atherosclerosis-journal.com/article/S0021-9150(20)31065-0/abstract